Skip to main content
Moberg Pharma logo

Moberg Pharma — Investor Relations & Filings

Ticker · MOB ISIN · SE0020353928 LEI · 549300XFXK7DVGDRP410 ST Manufacturing
Open in API
Filings indexed 785 across all filing types
Latest filing 2025-04-11 Annual Report (ESEF)
Country SE Sweden
Listing ST MOB

About Moberg Pharma

https://www.mobergpharma.com/

Moberg Pharma is a pharmaceutical company that develops and commercializes proprietary medical products, focusing on innovative drug delivery of proven compounds. The company's primary asset is MOB-015, a topical formulation for the treatment of onychomycosis (nail fungus). MOB-015 has demonstrated high fungal cure rates in Phase 3 clinical trials and has received market approval in multiple European countries. It is commercialized under the brand name Terclara® in Sweden and Norway, where it has achieved market leadership. Moberg Pharma's business model aims for lower development risk and faster market entry than traditional pharmaceutical development. The company's strategic goal is to establish MOB-015 as the leading global treatment for nail fungus.

Recent filings

Filing Released Lang Actions
Annual Report (ESEF) 2024
Annual Report (ESEF) Classification · 100% confidence FY 2024
2025-04-11 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding ('Innehavare') for Moberg Pharma AB (publ), specifically reporting a 'Köp' (Buy) transaction by an entity named How100.ai, resulting in a new total holding of 5.50002% of shares. This structure, focusing on insider/significant shareholder transactions and reporting changes in ownership percentage, directly corresponds to the definition of Director's Dealing or Major Shareholding Notification. Since the transaction is reported by an external entity (How100.ai) crossing a 5% threshold, it is most accurately classified as a Major Shareholding Notification (MRQ) or potentially Director's Dealing (DIRS) if the holder is an executive/director. Given the explicit reporting of crossing a 5% threshold ('Gränsvärde för antal aktier 5 %') and the detailed breakdown of share counts before and after the transaction, MRQ is the most precise fit, although DIRS is also plausible if the holder is an insider. However, the structure strongly resembles mandatory notifications of significant ownership changes. I will select MRQ as the primary classification for significant ownership changes.
2025-03-04 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding ('Antal aktier', 'Andel') by an entity ('Skandinaviska Enskilda Banken AB (publ)') in Moberg Pharma AB. It specifies the transaction reason ('Skäl för flaggning: Köp'), the date, and the resulting ownership percentage (5.43798%). This structure is characteristic of mandatory notifications regarding changes in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a general regulatory announcement (RNS), but a specific filing about insider/major shareholder transactions.
2025-02-17 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end report) for Moberg Pharma AB for the period Jan-Dec 2024. It contains comprehensive financial statements, including income statements, balance sheet items (liquid assets), and detailed management commentary on business performance, strategy, and market outlook. It is a substantive financial report for a period shorter than a full fiscal year (or in this case, the final quarterly/annual summary), fitting the definition of an Interim/Quarterly Report (IR). Q4 2024
2025-02-11 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Year-end report 2024' for Moberg Pharma AB. It contains comprehensive financial data for the full year and the fourth quarter of 2024, including revenue, EBITDA, EBIT, and earnings per share. It also includes management commentary, strategic updates, and operational highlights. As it is a comprehensive financial report for a period (full year) containing actual financial statements and analysis, it is classified as an Interim/Quarterly Report (IR), which is the standard category for year-end reports that are not the full 10-K/Annual Report filing. FY 2024
2025-02-11 English
Ny terbinafin-leverantör säkerställd
Regulatory Filings Classification · 100% confidence The document is a press release dated December 18, 2024, announcing that Moberg Pharma AB has secured a new supplier for terbinafine for their product MOB-015. It discusses supply chain milestones, regulatory processes (mentioning Läkemedelsverket/Swedish Medical Products Agency), and future launch plans. The text explicitly states that the information is being made public in accordance with the EU Market Abuse Regulation (MAR) and provides contact details for further information. This format—a brief, time-sensitive announcement of a material event that is not a full financial report (like 10-K or IR) or a specific transaction report (like DIRS or DIV)—fits best under general regulatory announcements. Since it is a formal announcement of a material business update under MAR, and it doesn't fit the specific categories like ER, CAP, or LTR, the most appropriate general category is Regulatory Filings (RNS). It is too detailed to be a simple Report Publication Announcement (RPA) which usually just points to another document.
2024-12-18 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.